Material Impact, who led the round, was joined by One Brave Idea and a number of prominent Angels, including John Abele, co-founder of Boston Scientific.
Bloomer is addressing the leading cause of death in women with the world’s first electrocardiogram device that looks and feels like a bra. By embedding patented, medical grade fabric sensors and machine learning algorithms into clothing worn daily by women, Bloomer provides users and physicians with unprecedented access to data on heart health.
“As women in STEM, we are well aware that digital health and AI tools are tailored to the people represented in the datasets. So when we realized that women were painfully underrepresented in clinical research, especially cardiovascular disease, we had to take action,” said Alicia Chong, CEO of Bloomer. “At Bloomer, we’re eliminating health imbalances by replacing an uncomfortable piece of plastic with a beautiful piece of clothing that empowers women to feel sexy instead of sick. This seamless and comfortable monitoring experience prevents algorithm biases and unlocks new, sex-specific digital biomarkers that can provide more accurate personalized care for patients. “That’s right.
The femtech sector has shown explosive growth, with almost $1 billion of funding going to femtech start-ups alone in 2019. Forbes predicts that space is set to become a $25 billion industry in the next five years. Material Impact, a Boston-based VC fund led by Bloomer’s round, sees the investment as central to its thesis of translating products made possible by material innovation into companies that solve real-world problems. In 2019, Material Impact led the NextGen Jane $9M Series A femtech startup. Adam Sharkawy, Co-Founder and Managing Partner of Material Impact and former Cardiovascular Health Officer, will serve as Bloomer’s Chairman of the Board of Directors.
“Bloomer addresses some of the gaping needs in cardiovascular health, one of the largest areas in healthcare overall,” said Sharkawy. “There has been little innovation in remote cardiac monitoring in clinical grade over the last several decades. Bloomer’s current soft electronics technology, combined with its elegant form factor, should allow effective remote monitoring of patients’ actual wear. In addition, the high-fidelity data they will collect will help fill a large gap in specific datasets for women, which may lead to better cardiovascular therapy for women. At Material Impact, we aim to invest in the category-creating companies that are ready to solve some of the world’s biggest problems. Alongside other investments in femtech, we are dedicated to building a focus on women’s health. “That’s right.
One Brave Idea, an investor in Bloomer, was set up to pursue unconventional scientific approaches in order to make major advances in the fight against coronary heart disease. Dr. Dr. Calum MacRae, who leads the One Brave Idea team, is the Vice Chair of Scientific Innovation at the Department of Medicine at Brigham and Women’s Hospital and Harvard Medical School.
“Our mission at One Brave Idea is to change the way coronary heart disease is detected, managed and prevented. To do this, we need to engage patients in new ways to break down the traditional barriers between patient care, research and their daily lives,” MacRae said. “Bloomer’s groundbreaking technology has the capability to monitor and identify new biologic mechanisms that contribute to heart disease. We’re really excited to work with Bloomer and their transformative patient-centered platform. “That’s right.
Bloomer has already had early training in women’s heart programs in leading hospitals in the Boston area. With pay-as-you-go pilots planned for 2020, Bloomer will use its seed funding to expand its pilot program, collect key clinical data and further develop commercial product and user experience.
It’s that emphasis on invisible user experience and a healthy relationship with technology that made Bloomer so fit to participate in Thrive Global’s “Project Entrepreneur” accelerator in 2018. There, Chong met Arianna Huffington, Founder and CEO of Thrive Global and Advisor to Bloomer, who was instrumental in helping MIT spinoff translate its big idea into business.
“Thrive Global’s mission is to end the stress and burn-out epidemic with sustainable, science-based solutions that unlock human potential and enhance well-being,” Huffington said. “Bloomer arms women with the tools they need to take their heart health into their own hands. It’s when we can understand how our lifestyle choices have an impact on our health outcomes that we really have the power to change our lives for the better. “That’s right.
Please visit www for more information on Bloomer Tech. Floomertech Come on,
About the Bloomer Technology
Bloomer Tech is a healthcare technology and service company focused on accelerating cardiovascular research and improving patient care. Bloomer is entering a new age of personalized diagnostics with the launch of the Bloomer Bra, the world’s first electrocardiogram device that looks and feels like a bra. Bloomer’s patented technology platform leverages over 20 years of evidence-based research showing gender and ethnic differences in the cardiovascular system, enabling women, researchers and caregivers to learn from each individual’s unique physiology and provide data-driven care. Bloomer Tech and its founders were supported by the MIT Legatum Center and were part of the MIT DeltaV accelerator at the Martin Trust Center, the MIT Integrated Design and Management Program and the MIT Computational Cardiovascular Research Group. Please visit www for more information. Floomertech Come on,
Material impact
Material Impact is a venture capital fund that invests in building companies that transform material technologies into products that have an impact on real world problems. Material Impact is based in Boston, Massachusetts. Visit http://www for more information. Impact of the material Come on,
About a Brave IdeaTM
One Brave Idea is a five-year, $85 million research and innovation initiative co-founded by the American Heart Association and Verily (formerly Google Life Sciences) with significant support from AstraZeneca and support from Quest Diagnostics to support Dr. Calum MacRae, Vice Chair of Scientific Innovation at Brigham and Women’s Hospital’s visionary approach to understanding and addressing coronary heart disease (CHD) and its devastating consequences. Visit https://www for more information. One-braveidea Organ
About the Global Thrive
Founded and led by Arianna Huffington, Thrive Global is a behavioral change technology company that helps individuals, companies and communities improve their well-being and performance. Thrive Global is headquartered in New York City and launched in the fall of 2016. Visit www for more information. The Global Prolife Come on,
Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Bloomer%20Tech/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co
